About the Authors

Zenjiro Sampei

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Tomoyuki Igawa

igawatmy@chugai-pharm.co.jp

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Tetsuhiro Soeda

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Yukiko Okuyama-Nishida

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Chifumi Moriyama

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Tetsuya Wakabayashi

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Eriko Tanaka

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Atsushi Muto

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Tetsuo Kojima

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Takehisa Kitazawa

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Kazutaka Yoshihashi

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Aya Harada

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Miho Funaki

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Kenta Haraya

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Tatsuhiko Tachibana

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Sachiyo Suzuki

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Keiko Esaki

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Yoshiaki Nabuchi

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Kunihiro Hattori

Affiliation Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

Competing Interests

All authors are employees of Chugai Pharmaceutical Co., Ltd. which is conducting the clinical study of hBS910 (ACE910). TS, T. Kojima and KH are inventors of the patents and patent applications which claim FVIII-mimetic bispecific antibodies to FIXa and FX. ZS, TI, TS, YON, CM, AM, T. Kojima, T. Kitazawa and KY are inventors of the patent application which claims hBS910, the investigational drug. These do not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Provided direction and guidance: YN. Provided the hypothesis of the bispecific antibody, directed and organized the program: K. Hattori. Conceived and designed the experiments: TI T. Kojima T. Kitazawa. Performed the experiments: ZS TI TS YON CM TW ET AM KY AH MF K. Haraya TT SS KE. Wrote the paper: ZS TI.